Clinical Nuclear Medicine · 1992 · 29 citations · 0 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic Nuclear MedicineDiagnostic RadiologyBone MetastasisBone Metastasis ImagingBone Tumor ImagingBreast Cancer ImagingMetastatic Bone DiseaseMetastatic Breast CancerBone Metastasis LocalizationBreast Cancer Bone Metastasis ImagingMetastatic Bone Disease DetectionMetastatic Bone Lesion ImagingRadionuclide Bone ImagingTc-99m Bone ScintigraphyTc-99m Methylene Diphosphonate ImagingTechnetium-99m Methylene Diphosphonate Imaging
Combined Tc-99m MDP skeletal imaging and Tc-99m(V) DMSA whole body scans to detect metastases were performed during the follow-up of 30 patients who underwent surgery for breast carcinoma. Eight patients had normal Tc-99m MDP and Tc-99m(V) DMSA scans and were declared free of metastatic disease, further confirmed by no change in symptomatology over a 1-year follow-up period. Twenty-two patients had positive Tc-99m MDP scans with varied skeletal involvement. Tc-99m(V) DMSA scans showed matched areas of increased radiotracer concentration in bony metastases in 20 of these patients. Tc-99m(V) DMSA concentration was not seen in traumatic vertebral collapse or in coexistent osteoarthritic disease in vertebral metastatic involvement. Interestingly, Tc-99m(V) DMSA showed increased concentration in brain and liver metastases. Pentavalent Tc-99m(V) DMSA appears useful for detecting skeletal and soft-tissue metastases in breast carcinoma, and can improve the specificity of Tc-99m MDP bone scans in screening for bone metastases.